NCT07325136 2026-03-09
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Recruiting
Bristol-Myers Squibb
Neonc Technologies, Inc.